Is MDLN a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Prime-vendor contracts in Supply Chain Solutions, with revenue (ttm) at ~$29.9B, up ~12%. The bear case rests on the clearest near-term risk is regulatory. Analysts covering it are spread from $40.00 to $62.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. The clearest near-term risk is regulatory. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $40.00, +9.1% from the $36.66 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

Prime-vendor contracts in Supply Chain Solutions. The distribution segment grew about 16.3 percent in the June 2026 quarter to roughly $4.1 billion, well ahead of the manufactured-brand side. The most optimistic analyst target on MDLN is $62.00, +69.1% from the $36.66 price. That figure is only reachable if this thesis works close to its best case.

The clearest near-term risk is regulatory. As of late June 2026 Medline had received three FDA warning letters covering facilities in Northfield, Illinois, Glens Falls, New York, and Waukegan, Illinois, with the Waukegan letter calling certain drug products adulterated after Bacillus cereus turned up in finished product samples on nine separate occasions between June 2023 and August 2025. Remediation costs money, can interrupt supply from specific plants, and invites further inspection. Second, the net margin is thin enough (roughly 2 percent trailing) that operational shocks like the Tracy distribution center fire, which cost about $336 million before insurance in the first half with another $50 million to $100 million expected in the second, dominate reported earnings even when the underlying business is fine. Third, tariffs and freight costs pass through a global sourcing base with a lag, and the second quarter figure was flattered by about $243 million of tariff refunds that will not repeat. Fourth, hospital group purchasing organizations negotiate hard and Cardinal Health, McKesson, and Owens & Minor all want the same shelf space. Finally, Blackstone, Carlyle, and Hellman & Friedman still hold a large block and have already run one $3.6 billion secondary at $41 per share, so supply overhang is a live factor in how the shares trade. Several shareholder law firms announced investigations following the FDA disclosure. The most pessimistic published target is $40.00, +9.1% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

Medline manufactures and distributes the everyday medical consumables that hospitals, surgery centers, physician offices, and nursing homes go through daily, at very large scale and thin margins.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Prime-vendor contracts in Supply Chain Solutions) stalling in the reported numbers rather than in the narrative, the risk above (the clearest near-term risk is regulatory) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

Consumable medical supplies, not devices or drugs in any meaningful volume. Think exam gloves, surgical gowns and drapes, sterile procedure kits, wound care, incontinence and skin care products, patient apparel, and lab and diagnostic consumables. It both manufactures these under the Medline label and distributes other companies' brands. Customers are hospitals, ambulatory surgery centers, physician offices, and long-term care facilities, with about 90 percent of revenue generated in the United States.

Medline priced its IPO at $29 per share on December 16, 2025, and began trading on Nasdaq on December 17. It raised about $6.26 billion across roughly 216 million shares, the largest IPO globally that year. The stock opened at $35 and closed its first day above $41, valuing the company near $54 billion. Most of the proceeds went to repaying about $4 billion of debt left from the 2021 leveraged buyout.

The second quarter 2026 report on August 5 paired good revenue news with a guidance cut. Sales grew about 11.6 percent to roughly $7.7 billion and organic growth guidance was raised, but full-year adjusted EBITDA guidance came down to $3.3 to $3.4 billion from $3.5 to $3.6 billion. Management cited the Tracy distribution center fire, quality remediation spending, Middle East conflict inflation on fuel and product costs, and retail softness. Shares fell roughly 13 percent.